Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples

Background - For epidemiologic, social and economic reasons, assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection prevalence and immunity are important to adapt decisions to current demands. Hence, immunoassays for detection of anti-SARS-CoV-2 antibodies are introduce...

Full description

Saved in:
Bibliographic Details
Main Authors: Haselmann, Verena (Author) , Kittel, Maximilian (Author) , Gerhards, Catharina (Author) , Thiaucourt, Margot (Author) , Eichner, Romy (Author) , Costina, Victor (Author) , Neumaier, Michael (Author)
Format: Article (Journal)
Language:English
Published: 9 July 2020
In: Clinica chimica acta
Year: 2020, Volume: 510, Pages: 73-78
ISSN:1873-3492
DOI:10.1016/j.cca.2020.07.007
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/j.cca.2020.07.007
Verlag, lizenzpflichtig, Volltext: http://www.sciencedirect.com/science/article/pii/S0009898120303235
Get full text
Author Notes:Verena Haselmann, Maximilian Kittel, Catharina Gerhards, Margot Thiaucourt, Romy Eichner, Victor Costina, Michael Neumaier

MARC

LEADER 00000caa a2200000 c 4500
001 1743813627
003 DE-627
005 20240408193243.0
007 cr uuu---uuuuu
008 210104s2020 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.cca.2020.07.007  |2 doi 
035 |a (DE-627)1743813627 
035 |a (DE-599)KXP1743813627 
035 |a (OCoLC)1341384397 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Haselmann, Verena  |d 1982-  |e VerfasserIn  |0 (DE-588)1153803097  |0 (DE-627)1015321275  |0 (DE-576)500568154  |4 aut 
245 1 0 |a Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples  |c Verena Haselmann, Maximilian Kittel, Catharina Gerhards, Margot Thiaucourt, Romy Eichner, Victor Costina, Michael Neumaier 
264 1 |c 9 July 2020 
300 |a 6 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 03.02.2021 
520 |a Background - For epidemiologic, social and economic reasons, assessment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection prevalence and immunity are important to adapt decisions to current demands. Hence, immunoassays for detection of anti-SARS-CoV-2 antibodies are introduced rapidly without requiring FDA emergency use authorization approval. Thus, evaluation of test performance predominantly relies on laboratories. This study aimed to evaluate the test performance of recently launched commercial immunoassays in serum and plasma samples. - Methods - 51 serum samples from 26 patients with confirmed SARS-CoV-2 infection after end of quarantine and 25 control patients were analyzed using anti-SARS-CoV-2 IgG immunoassays from Roche, Euroimmun and Epitope to assess diagnostic sensitivity and specificity. 20 matching pairs of serum and plasma samples were included to analyze comparability between different specimens. - Results - Overall, a diagnostic sensitivity of 92.3%, 96.2-100% and 100% with a respective diagnostic specificity of 100%, 100% and 84-86% for the immunoassays from Roche, Euroimmun and Epitope were determined. In total, 84-96% of samples were correctly classified as negative and 92.3-95.2% as positive. The level of concordance between plasma- and serum-based testing diverged between the assays (Epitope r2 = 0.97; Euroimmun r2 = 0.91; Roche r2 = 0.76). - Conclusions - The immunoassays from Euroimmun and Roche revealed a higher specificity than the Epitope assay without a substantial drop of diagnostic sensitivity. Significant differences between plasma- and serum-based testing highlights the need for determination of appropriate cut-offs per specimen type. Hence, there is an urgent need for test harmonization and establishment of quality standards for an appropriate use of COVID-19 serological tests. 
650 4 |a Anti-SARS-CoV-2 
650 4 |a COVID-19 
650 4 |a Immunoassay 
650 4 |a Method comparison 
650 4 |a Roche 
650 4 |a Serologic assay 
700 1 |a Kittel, Maximilian  |d 1987-  |e VerfasserIn  |0 (DE-588)1156691699  |0 (DE-627)1019529741  |0 (DE-576)502380136  |4 aut 
700 1 |a Gerhards, Catharina  |d 1992-  |e VerfasserIn  |0 (DE-588)1226262503  |0 (DE-627)1747234710  |4 aut 
700 1 |a Thiaucourt, Margot  |d 1993-  |e VerfasserIn  |0 (DE-588)1156311373  |0 (DE-627)1018863850  |4 aut 
700 1 |a Eichner, Romy  |e VerfasserIn  |0 (DE-588)1160452911  |0 (DE-627)1023627698  |0 (DE-576)505899973  |4 aut 
700 1 |a Costina, Victor  |e VerfasserIn  |0 (DE-588)1058239481  |0 (DE-627)796639973  |0 (DE-576)414278186  |4 aut 
700 1 |a Neumaier, Michael  |d 1958-  |e VerfasserIn  |0 (DE-588)1028284934  |0 (DE-627)730532623  |0 (DE-576)375780580  |4 aut 
773 0 8 |i Enthalten in  |t Clinica chimica acta  |d Amsterdam [u.a.] : Elsevier Science, 1956  |g 510(2020), Seite 73-78  |h Online-Ressource  |w (DE-627)306654423  |w (DE-600)1499920-1  |w (DE-576)094531242  |x 1873-3492  |7 nnas  |a Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples 
773 1 8 |g volume:510  |g year:2020  |g pages:73-78  |g extent:6  |a Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples 
856 4 0 |u https://doi.org/10.1016/j.cca.2020.07.007  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0009898120303235  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20210203 
993 |a Article 
994 |a 2020 
998 |g 1028284934  |a Neumaier, Michael  |m 1028284934:Neumaier, Michael  |d 60000  |d 63300  |e 60000PN1028284934  |e 63300PN1028284934  |k 0/60000/  |k 1/60000/63300/  |p 7  |y j 
998 |g 1058239481  |a Costina, Victor  |m 1058239481:Costina, Victor  |d 60000  |d 63300  |e 60000PC1058239481  |e 63300PC1058239481  |k 0/60000/  |k 1/60000/63300/  |p 6 
998 |g 1160452911  |a Eichner, Romy  |m 1160452911:Eichner, Romy  |d 60000  |d 63300  |e 60000PE1160452911  |e 63300PE1160452911  |k 0/60000/  |k 1/60000/63300/  |p 5 
998 |g 1156311373  |a Thiaucourt, Margot  |m 1156311373:Thiaucourt, Margot  |d 60000  |d 63300  |e 60000PT1156311373  |e 63300PT1156311373  |k 0/60000/  |k 1/60000/63300/  |p 4 
998 |g 1226262503  |a Gerhards, Catharina  |m 1226262503:Gerhards, Catharina  |d 60000  |d 63300  |e 60000PG1226262503  |e 63300PG1226262503  |k 0/60000/  |k 1/60000/63300/  |p 3 
998 |g 1156691699  |a Kittel, Maximilian  |m 1156691699:Kittel, Maximilian  |d 60000  |d 63300  |e 60000PK1156691699  |e 63300PK1156691699  |k 0/60000/  |k 1/60000/63300/  |p 2 
998 |g 1153803097  |a Haselmann, Verena  |m 1153803097:Haselmann, Verena  |d 60000  |e 60000PH1153803097  |k 0/60000/  |p 1  |x j 
999 |a KXP-PPN1743813627  |e 3848376849 
BIB |a Y 
SER |a journal 
JSO |a {"recId":"1743813627","name":{"displayForm":["Verena Haselmann, Maximilian Kittel, Catharina Gerhards, Margot Thiaucourt, Romy Eichner, Victor Costina, Michael Neumaier"]},"origin":[{"dateIssuedDisp":"9 July 2020","dateIssuedKey":"2020"}],"id":{"doi":["10.1016/j.cca.2020.07.007"],"eki":["1743813627"]},"type":{"bibl":"article-journal","media":"Online-Ressource"},"language":["eng"],"physDesc":[{"extent":"6 S."}],"title":[{"title":"Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples","title_sort":"Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samples"}],"person":[{"family":"Haselmann","role":"aut","given":"Verena","display":"Haselmann, Verena"},{"family":"Kittel","role":"aut","given":"Maximilian","display":"Kittel, Maximilian"},{"family":"Gerhards","given":"Catharina","role":"aut","display":"Gerhards, Catharina"},{"display":"Thiaucourt, Margot","role":"aut","given":"Margot","family":"Thiaucourt"},{"display":"Eichner, Romy","family":"Eichner","role":"aut","given":"Romy"},{"given":"Victor","role":"aut","family":"Costina","display":"Costina, Victor"},{"role":"aut","given":"Michael","family":"Neumaier","display":"Neumaier, Michael"}],"relHost":[{"recId":"306654423","disp":"Comparison of test performance of commercial anti-SARS-CoV-2 immunoassays in serum and plasma samplesClinica chimica acta","origin":[{"publisher":"Elsevier Science","dateIssuedKey":"1956","dateIssuedDisp":"1956-","publisherPlace":"Amsterdam [u.a.]"}],"id":{"eki":["306654423"],"zdb":["1499920-1"],"issn":["1873-3492"]},"part":{"text":"510(2020), Seite 73-78","extent":"6","volume":"510","pages":"73-78","year":"2020"},"note":["Gesehen am 04.02.20"],"type":{"bibl":"periodical","media":"Online-Ressource"},"pubHistory":["1.1956 -"],"physDesc":[{"extent":"Online-Ressource"}],"language":["eng"],"title":[{"title_sort":"Clinica chimica acta","subtitle":"international journal of clinical chemistry and applied molecular biology","title":"Clinica chimica acta"}]}],"note":["Gesehen am 03.02.2021"]} 
SRT |a HASELMANNVCOMPARISON9202